Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients

Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients

The use of neuromuscular blocking agents (NMBA) in ARDS patients has not been extensively investigated. The aim of the study is to show a reduction of the mortality rate of ARDS patients.

The use of neuromuscular blocking agents (NMBA) in ARDS patients has not been extensively investigated. It has been recently demonstrated that a systematic 48-h infusion of NMBA is associated with a significant improvement in oxygenation as compared with a control group (Gainnier et al., Crit Care Med 2004). Moreover, a trend towards a reduction in the mortality rate has been observed. The aim of the study is to show a reduction of the mortality rate of ARDS patients.

Inclusion Criteria:

• ARDS with a PaO2 / FiO2 < 150 with a PEEP > 5 since less than 48 hrs
• informed consent

Exclusion Criteria:

• NMBA allergy
• Continuous administration of NMBA for ARDS prior inclusion
• Age < 18 yrs
• SAPS II > 70
• Persistent air leak